HUTCHMED launches global Phase I trial of HMPL-A830 KRAS-EGFR antibody-drug conjugate in solid tumors

• HUTCHMED launched the Phase Ia segment of a global first-in-human study of HMPL-A830 in advanced solid tumors.
• Initial results have not been presented; the trial will generate early safety and preliminary efficacy readouts.
• Program aims to deliver tumor-targeted KRAS inhibition while also blocking EGFR signaling, seeking more durable activity with improved tolerability.
• First patient was dosed in China on Sept. 24, 2026; the study will set an expansion dose for selected tumor types.
• GSK holds rights outside Greater China under a Sept. 3, 2026 license; HUTCHMED is running global Phase I development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609272000PRIMZONEFULLFEED9834018) on September 28, 2026, and is solely responsible for the information contained therein.